Methods of decreasing tumor volume and reducing tumor burden using TNF-receptor-coupling agents
View Patent ↗Receptor coupling agents, including multivalent constructs comprising anti-TNF receptor binding moieties, for treating cancer and inhibiting tumor volume in a subject are disclosed.
1. A method of decreasing tumor volume comprising administering to a subject an effective amount of a receptor coupling agent comprising at least two components which specifically crosslinks at least two distinct TNF family receptor types, and induces formation of heteromeric TNF receptor complexes, wherein the receptor coupling agent comprises a first binding specificity directed to TRAIL-R2, and a second binding specificity directed to Lymphotoxin-β-Receptor (LTβR), and wherein the first and second binding specificities are conferred by a component selected from the group consisting of an antibody, an antigen binding fragment thereof, an scFv molecule, and a ligand to the TNF receptor, and wherein the tumor is a solid tumor.
2. The method of claim 1 , wherein the receptor coupling agent is administered in the presence of IFNγ.
3. The method of claim 1 , wherein the receptor coupling agent is administered in the presence of a chemotherapeutic agent.
4. A method of reducing tumor burden comprising administering to a subject an effective amount of a receptor coupling agent comprising at least two components which specifically crosslinks at least two distinct TNF family receptor types, and induces formation of heteromeric TNF receptor complexes, wherein the receptor coupling agent comprises a first binding specificity directed to TRAIL-R2, and a second binding specificity directed to Lymphotoxin-β-Receptor (LTβR), and wherein the first and second binding specificities are conferred by a component selected from the group consisting of an antibody, an antigen binding fragment thereof, an scFv molecule, and a ligand to the TNF receptor, and wherein the cancer is a solid tumor.
5. The method of claim 4 , wherein the receptor coupling agent is administered in the presence of IFNγ.
6. The method of claim 4 , wherein the receptor coupling agent is administered in the presence of a chemotherapeutic agent.
7. The method of claim 1 or 4 , wherein the first or second binding specificity is conferred by an antibody or antigen binding fragment thereof.
8. The method of claim 1 or 4 , wherein at least the first or second binding specificity is conferred by a single chain Fv fragment.
9. The method of claim 1 or 4 , wherein the first or second binding specificity is conferred by a natural ligand for the receptor and the remaining binding specificity is conferred by an antibody, or an antigen binding fragment thereof.
10. The method of claim 1 or 4 , wherein at least one of the TNF receptors is overexpressed on tumor cells.
11. The method of claim 10 , wherein at least one of the TNF receptors is not overexpressed on normal liver or endothelial cells.
12. The method of claim 1 or 4 , wherein the second binding specificity is conferred by an anti-LTβ receptor (LTβR) antibody, or antigen binding fragment thereof.
13. The method of claim 12 , wherein the anti-LTβR antibody, or antigen binding fragment thereof is derived from a humanized CBE11 antibody.
14. The method of claim 12 , wherein the first binding specificity is conferred by an anti- TRAIL-R2 antibody, or antigen binding fragment thereof.
15. The method of claim 14 , wherein the anti-TRAIL-R2 antibody, or antigen binding fragment thereof is derived from a humanized 14A2 antibody.
16. The method of claim 1 or 4 , wherein the second binding specificity is conferred by a humanized CBE11 antibody or antigen binding fragment thereof, and the first binding specificity is conferred by a humanized 14A2 antibody or antigen binding fragment thereof.
17. The method of claim 1 or 4 , wherein the first or second binding specificity is conferred by at least two trimeric ligand-Fc constructs and the remaining binding specificity is conferred by three antibodies.
18. The method of claim 1 or 4 , wherein at least one of the TNF family receptors is not normally found in a raft environment on the cell surface.
19. The method of claim 1 or 4 , wherein at least one of the TNF family receptors is normally found in a raft environment on the cell surface.
20. A method of decreasing tumor volume comprising administering to a subject an effective amount of a bispecific antibody comprising a first and a second binding specificity and at least four antigen binding sites, which bispecific antibody induces formation of a heteromeric receptor complex, said bispecific antibody comprising a first binding specificity directed to TRAIL-R2, and a second binding specificity directed to LTβR.
21. The method of claim 20 , wherein the second binding specificity is derived from a anti-LTβR antibody, antigen binding fragment thereof, or an scFv molecule.
22. The method of claim 21 , wherein the anti-LTβR antibody, antigen binding fragment thereof, or scFv molecule is derived from a humanized CBE11 antibody.
23. The method of claim 20 , wherein the first binding specificity is derived from an anti- TRAIL-R2 antibody, antigen binding fragment thereof, or an scFv molecule.
24. The method of claim 23 , wherein the anti-TRAIL-R2 antibody,-antigen binding fragment thereof, or scFv molecule is derived from a humanized 14A2 antibody.
25. A method of decreasing tumor volume comprising administering to a subject an effective amount of an antibody comprising at least a first and a second binding specificity and at least four antigen binding sites, which antibody crosslinks at least two distinct TNF family receptors and induces formation of a heteromeric receptor complex, the antibody comprising a first binding specificity directed to LTBR and a second binding specificity directed to TRAIL-R2.
26. The method of claim 25 , wherein the LTBR binding specificity is provided by an antibody or a single chain variable region.
27. The method of claim 25 , wherein the LTBR binding specificity is provided by an antigen binding fragment of an antibody, wherein the antigen binding fragment is selected from the group comprising a Fab fragment, a F(ab) 2 fragment, and a F v fragment.
28. The method of claim 25 , wherein the LTBR binding specificity is provided by a ligand.
29. The method of claim 25 , wherein the TRAIL-R2 binding specificity is provided by an antibody or a single chain variable region.
30. The method of claim 25 , wherein the TRAIL-R2 binding specificity is provided by an antigen binding fragment of an antibody, wherein the antigen binding fragment is selected from the group comprising a Fab fragment, a F(ab) 2 fragment, and a F v fragment.
31. The method of claim 25 , wherein the TRAIL-R2 binding specificity is provided by a ligand.
32. The method of claim 25 , wherein the antibody comprises a heavy chain comprising an amino acid sequence set forth as SEQ ID NO: 6 and a light chain comprising an amino acid sequence set forth as SEQ ID NO: 8.